Q linea AB Total Liabilities
Q linea AB total liabilities. Based on the latest financial reports, Q linea AB (QLINEA) has total liabilities worth Skr29.06 Million SEK (≈ $3.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check QLINEA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Q linea AB (2015–2025)
Total liabilities of Q linea AB from 2015 to 2025. This chart illustrates how Q linea AB's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Q linea AB's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Q linea AB Competitors by Total Liabilities
The table below lists competitors of Q linea AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Modi Rubber Limited
NSE:MODIRUBBER
|
India | Rs-6.77 Billion |
|
Nova Wellness Group Bhd
KLSE:0201
|
Malaysia | RM8.89 Million |
|
Trajectory Alpha Acquisition Corp
NYSE:TCOA
|
USA | $9.81 Million |
|
Vitreous Glass Inc
V:VCI
|
Canada | CA$1.50 Million |
|
AfroCentric Investment Corp
JSE:ACT
|
South Africa | ZAC2.12 Billion |
|
Shinfox Energy Co Ltd
TW:6806
|
Taiwan | NT$43.23 Billion |
|
Aaron Industries Limited
NSE:AARON
|
India | Rs-486.12 Million |
|
Zenith Minerals Ltd
AU:ZNC
|
Australia | AU$974.40K |
Liability Composition Analysis (2015–2025)
This chart breaks down Q linea AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Q linea AB's balance sheet.
Liquidity & Leverage Metrics
Q linea AB Total Liabilities Ratios Explained
Q linea AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Q linea AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Q linea AB (2015–2025)
The table below shows the annual total liabilities of Q linea AB from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr31.66 Million ≈ $3.41 Million |
-81.95% |
| 2024-12-31 | Skr175.45 Million ≈ $18.88 Million |
+314.37% |
| 2023-12-31 | Skr42.34 Million ≈ $4.56 Million |
-7.47% |
| 2022-12-31 | Skr45.76 Million ≈ $4.92 Million |
+27.65% |
| 2021-12-31 | Skr35.84 Million ≈ $3.86 Million |
+11.89% |
| 2020-12-31 | Skr32.03 Million ≈ $3.45 Million |
-4.26% |
| 2019-12-31 | Skr33.46 Million ≈ $3.60 Million |
+30.66% |
| 2018-12-31 | Skr25.61 Million ≈ $2.76 Million |
+51.67% |
| 2017-12-31 | Skr16.89 Million ≈ $1.82 Million |
+100.84% |
| 2016-12-31 | Skr8.41 Million ≈ $904.73K |
+51.37% |
| 2015-12-31 | Skr5.55 Million ≈ $597.70K |
-- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more